These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

972 related items for PubMed ID: 3260908

  • 1. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 2. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T, Shu S.
    J Immunol; 1987 Sep 15; 139(6):2103-9. PubMed ID: 2957448
    [Abstract] [Full Text] [Related]

  • 3. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
    Shu S, Chou T, Rosenberg SA.
    Cancer Res; 1987 Mar 01; 47(5):1354-60. PubMed ID: 3102046
    [Abstract] [Full Text] [Related]

  • 4. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K, Chang AE, Shu SY.
    Cancer Res; 1990 Jul 15; 50(14):4371-6. PubMed ID: 2114215
    [Abstract] [Full Text] [Related]

  • 5. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S, Rosenberg SA.
    J Immunol; 1985 Oct 15; 135(4):2895-903. PubMed ID: 2411817
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ, Yang JC, Afreniere RL, Shu SY, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):285-94. PubMed ID: 3108401
    [Abstract] [Full Text] [Related]

  • 8. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY, Chou T, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):295-304. PubMed ID: 2953816
    [Abstract] [Full Text] [Related]

  • 9. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T, Chang AE, Shu SY.
    J Immunol; 1988 Apr 01; 140(7):2453-61. PubMed ID: 2450925
    [Abstract] [Full Text] [Related]

  • 10. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 11. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
    Chou T, Bertera S, Chang AE, Shu S.
    J Immunol; 1988 Sep 01; 141(5):1775-81. PubMed ID: 3261761
    [Abstract] [Full Text] [Related]

  • 12. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S, Chou T, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3891-8. PubMed ID: 3486223
    [Abstract] [Full Text] [Related]

  • 13. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 14. Relationship among function, phenotype, and specificity in primary allospecific T cell populations: identification of phenotypically identical but functionally distinct primary T cell subsets that differ in their recognition of MHC class I and class II allodeterminants.
    Golding H, Mizuochi T, McCarthy SA, Cleveland CA, Singer A.
    J Immunol; 1987 Jan 01; 138(1):10-7. PubMed ID: 2946773
    [Abstract] [Full Text] [Related]

  • 15. Contrasuppressor cells that break oral tolerance are antigen-specific T cells distinct from T helper (L3T4+), T suppressor (Lyt-2+), and B cells.
    Kitamura K, Kiyono H, Fujihashi K, Eldridge JH, Green DR, McGhee JR.
    J Immunol; 1987 Nov 15; 139(10):3251-9. PubMed ID: 3500210
    [Abstract] [Full Text] [Related]

  • 16. T-cell immunity to murine Moloney sarcoma virus-induced tumours: L3T4+ T cells are necessary for resistance to primary sarcoma growth, but Lyt-2+ T cells are required for resistance to secondary tumour cell challenge.
    Bateman WJ, Jenkinson EJ, Owen JJ.
    Immunology; 1987 Jul 15; 61(3):317-20. PubMed ID: 2956180
    [Abstract] [Full Text] [Related]

  • 17. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
    Reichert CM, Rosenstein M, Von Glatz J, Hsu SM, Rosenberg SA.
    Lab Invest; 1985 Mar 15; 52(3):304-13. PubMed ID: 3974201
    [Abstract] [Full Text] [Related]

  • 18. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
    Ohnishi K, Bonavida B.
    J Immunol; 1987 Jun 15; 138(12):4524-9. PubMed ID: 2953807
    [Abstract] [Full Text] [Related]

  • 19. Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis.
    Sugihara S, Izumi Y, Yoshioka T, Yagi H, Tsujimura T, Tarutani O, Kohno Y, Murakami S, Hamaoka T, Fujiwara H.
    J Immunol; 1988 Jul 01; 141(1):105-13. PubMed ID: 2967864
    [Abstract] [Full Text] [Related]

  • 20. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep 01; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.